Navigation Links
Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues

LANSING, Mich., Sept. 24 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) announced today that its revenues for the first quarter of FY 2010, which ended Aug. 31, increased 12% from the previous year's first quarter to $32,347,000. First quarter net income increased 18% from the prior year's $3,733,000 to $4,395,000, or to $0.29 per share in the current year compared to the previous year's $0.25.

Neogen's first quarter revenues, net income, and earnings per share all represent quarterly records for the 27-year-old company. The company's record quarter came despite currency exchange rates that had an unfavorable impact of $1.0 million on Neogen's international net sales when compared to the prior year's first quarter.

"The first quarter was a great start for our new fiscal year as our food and animal safety strategy continues to gain worldwide strength," said James Herbert, Neogen's chief executive officer and chairman. "We are able to report that we grew our top line at a double-digit pace, and our profitability at a pace that exceeded revenue growth. These results provide further evidence of improving efficiencies and general operational strength throughout Neogen."

The quarter marked the 66th consecutive profitable quarter from operations for the company, and was the 70th of the past 75 quarters when Neogen reported revenue increases as compared with the previous year.

"We are obviously pleased to report that the 23% increase in our operating profit was approximately double the percentage increase in our revenues," said Lon Bohannon, Neogen's president and chief operating officer. "We believe that our growth performance at the operating profit line is evidence of our commitment to control costs as our revenues advance. The only expense category that increased faster than our revenue growth was our planned investment in research and development. We are very pleased to be able to accelerate our R&D spending for Neogen's future, and still report today's exceptional results."

Largely the result of a favorable product mix that included a greater percentage of diagnostic products, Neogen's gross margin increased to 53.4% of sales in its first quarter of the current year, compared to 51.4% of sales in its FY 2009 first quarter. Neogen's operating income for the first quarter equaled 21.5% of the company's quarterly revenues.

"As our consolidated balance sheet data shows, we had an exceptional quarter generating cash, and we now have more than $23 million in cash and investments to pursue a wide variety of growth strategies," said Richard Current, Neogen's chief financial officer. "Our inventories are down in comparison to our prior quarter, as we continue our progress in controlling the level of inventories without impacting sales. Our accounts receivable have increased slightly, but at a pace less than our sales increase. We continue to monitor the financial health of our customers to avoid collection concerns, and have yet to experience significant receivable problems."

Neogen's Food Safety and Animal Safety Divisions posted nearly identical 12% revenue increases in the first quarter compared to the prior year's first quarter. The food safety sales increase was entirely organic, while the year-over-year animal safety increase benefited from the July 2008 acquisition of DuPont cleaners and disinfectants, and the May 2009 acquisition of International Diagnostic Systems (IDS). Acquired IDS products include a number of drug detection diagnostics. Company-wide, Neogen's organic sales grew approximately 9% in the quarter compared to the prior year's first quarter.

The company's quarterly food safety sales improvement was led by a more than 30% increase in sales of its dairy antibiotic diagnostics. Neogen's product line to detect dairy antibiotics was recently bolstered by the launch of BetaStar((R)) Combo, which is the fastest diagnostic available for detecting beta-lactam and tetracycline antibiotic residues in milk. Tetracyclines are more widely used for treatment of bovine mastitis in the European Union than elsewhere.

Sales of Neogen's innovative rapid tests for food allergens continued their strong advance, improving approximately 25% in the current quarter compared to the prior year's first quarter. This performance was the result of significant increases in sales of diagnostic tests to detect milk, egg, almond, and gluten residues. Food processors continue to expand routine testing procedures to help prevent inadvertent contamination from reaching food allergic consumers.

Sales of the company's tests for natural toxins increased by 10% in the quarter compared to the prior year's first quarter, led by increases in sales of test kits to detect deoxynivalenol (DON) and histamine. The DON test sales increase came largely as the result of reports of high levels of the mold toxin DON in harvested grain in isolated pockets of the United States, and continuing market acceptance of the company's new test system. Histamine is a toxin produced in certain types of harvested fish, especially tuna, if they are improperly stored and transported.

Quarterly sales growth for the company's Animal Safety Division was led by an approximately 30% increase in the current quarter compared to the prior year's first quarter in products sold to veterinarians through ethical market channels. This exceptional growth included a 60% increase in sales of the company's two veterinary biologics: BotVax((R)) B, an equine botulism vaccine, and EqStim((R)), an immune system stimulant. The quarter-over-quarter increase also included an approximately 60% improvement of sales in the quarter of Neogen's veterinary vitamin injectables that are used primarily for prevention and treatment of vitamin deficiencies in cattle and sheep.

Sales of veterinary products through over-the-counter distributor channels were led by strong increases in sales of products to treat wounds, and leg and foot conditions. The company's Ideal Instruments brand, including disposable needles and syringes, also had a solid quarter with sales growth of 11% compared to the previous year's first quarter.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases, and sanitation concerns, and dehydrated culture media. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

    (In thousands, except for percentages and per share amounts)

                                         Ended Aug. 31
                                        2009      2008
                                        ----      ----
        Food Safety                  $17,476   $15,549
        Animal Safety                 14,871    13,256
                                      ------    ------
     Total revenue                    32,347    28,805
     Cost of sales                    15,077    14,001
                                      ------    ------
     Gross margin                     17,270    14,804
     Other expenses
        Sales & marketing              5,972     5,619
        Administrative                 2,890     2,580
        Research & development         1,464       952
                                       -----       ---
     Total other expenses             10,326     9,151
                                      ------     -----
     Operating income                  6,944     5,653
     Other revenue                        51       205
     Income before tax                 6,995     5,858
     Income tax                        2,600     2,125
                                       -----     -----
     Net income                       $4,395    $3,733
     Net income per diluted share      $0.29     $0.25

     Other information:
        Shares to calculate per
         share                        15,257    15,031
        Depreciation &
         amortization                 $1,012      $948
        Interest income                   17        65
        Gross margin (% of sales)       53.4%     51.4%
        Operating income (% of
         sales)                         21.5%     19.6%
        Revenue increase vs. FY 2009    12.3%
        Net income increase vs. FY 2009 17.7%

    (In thousands)

                                                 Aug. 31      May 31
                                                    2009        2009
     Current assets
             Cash & investments                  $23,564     $13,842
             Accounts receivable                  24,094      23,363
             Inventory                            30,471      31,363
             Other current assets                  3,074       3,198
                                                   -----       -----
     Total current assets                         81,203      71,766
     Property & equipment                         17,265      17,058
     Goodwill & other assets                      53,105      53,352
                                                  ------      ------
     Total assets                               $151,573    $142,176

     Liabilities & Stockholders' Equity
     Current liabilities                         $12,396      $9,246
     Long-term lines of credit                         -           -
     Other long-term liabilities                   4,277       4,251
     Stockholders' equity-shares outstanding
             14,842 in Aug. & 14,737 in May      134,900     128,679
                                                 -------     -------
     Total liabilities & stockholders' equity   $151,573    $142,176

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.

SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neogen Acquires Kane Enterprises
2. Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues
3. Neogen Acquires Assets of Rivard Instruments
4. Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues
5. Neogen Launches Quickest Test Available for Tetracyclines in Milk
6. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
7. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results
8. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
9. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
10. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
11. Neogen Forms Mexican Subsidiary
Post Your Comments:
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions to ... symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory science, ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
Breaking Biology News(10 mins):